Navigation Links
Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
Date:1/30/2008

TEL AVIV, Israel, January 30 /PRNewswire-FirstCall/ -- TopSpin Medical, Inc. (TASE: TOPMD) announces first commercial installation of the Cathamaran(TM) Intravascular MRI System at ZOL Hospital, Genk, Belgium, with the first procedures performed on January 16th.

"We are pleased to be the first site to install the Cathamaran(TM) IVMRI System. This 6F compatible technology represents a major breakthrough in our ability to detect and quantify lipid present in coronary lesions. We are very excited to be among the first centers to participate in the MIRACLE Study to further evaluate the clinical role for IVMRI in both diagnostic and interventional coronary catheterization procedures. The identification of high risk, lipid -rich lesions that may be prone to rupture is of paramount importance, and the IVMRI System may potentially help address this unmet need," stated Dr. M. Vrolix from ZOL hospital, Belgium.

The company and the distributor are currently in advance negotiation for similar agreements with additional medical centers in the Benelux territory. The company is expecting to install additional Cathamaran(TM) Intravascular MRI systems in the Benelux territory in the course of the current quarter.

The Cathamaran(TM) IVMRI System will be used in a post-market Study of coronary plaque lipid characterization by IVMRI performed during diagnostic or interventional catheterization [MIRACLE Study]. The multi-national prospective MIRACLE Study is designed to collect data on a widespread post-market clinical experience to evaluate how lipid quantification with the IVMRI System may be used to guide patient treatment.

Yaron Tal, President and Chief Executive Officer of TopSpin Medical, said: "The introduction of our unique Cathamaran(TM) Intravascular MRI System and the initiation of the MIRACLE Registry represent major milestones for our company. We are committed to advancing investigation into vulnerable plaque with the goal of improving diagnosis of these high-risk lesions and aiding development of appropriate therapeutic solutions. We are very excited to collaborate with ZOL hospital in this important investigation."

About TopSpin

Topspin Medical(TASE: TOPMD), Inc. founded in 1999 and headquartered in Lod, Israel, is a publicly traded company focused on developing and commercializing real time therapy guidance systems based on a novel magnetic resonance imaging technology.

The company's technological development is unique because of the miniaturization of the device, its ability to characterize soft tissues in greater precision and resolution and to provide the physician results in real-time. The use of the novel technology may constitute a platform in many fields where characterizing soft tissues in high resolution is of critical importance for diagnosing and treating the disease. In addition, the innovation allows greater access to MRI technology thanks to the size of the device, the simplicity of its use and its low cost.

The technology's first application in the cardiology field is targeted to aid the diagnosis and treatment of vascular disease. The company has developed the only 6F compatible MRI probe designed for intravascular delivery in the coronary arteries. The company has recently submitted a 510K with the FDA and received the CE Mark for its second generation in August 2007.

In 2006 TopSpin Medical began to develop its technology for imaging prostate cancer by an integrated endo-rectal MRI and ultrasound probe.

For more information about Topspin Medical, visit the company's website at http://www.Topspin.co.il

Forward-looking Statements

Statements in this press release which are not historical data are forward-looking statements which involve known and unknown risks, uncertainties or other factors not under the company's control, which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the company's periodic filings with the securities authorities.

Contact:

Eyal Kolka

CFO & Senior Vice President, Business Development

+972-8-920-0033

eyal@topspin.co.il


'/>"/>
SOURCE TopSpin Medical Israel Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Top Spin Appoints Yaron Tal President and Chief Executive Officer, Erez Golan, TopSpin Medicals Founder and Current Chief Executive Officer, Will Continue as a Board Member and Consultant
2. TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs
3. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. BioMS Medical announces its intention to renew a normal course issuer bid
9. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
10. ATS Medical Expands Open Pivot Heart Valve Offerings
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):